The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BVS | -44.11% | N/A | N/A | -63% |
| S&P | +15.06% | +95.03% | +14.29% | +72% |
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $147.66M | -2.4% |
| Gross Profit | $100.65M | -0.9% |
| Gross Margin | 68.16% | 1.0% |
| Market Cap | $439.29M | 19.7% |
| Market Cap / Employee | $0.47M | 0.0% |
| Employees | 930 | -4.1% |
| Net Income | $9.27M | 128.9% |
| EBITDA | $30.67M | 63.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $32.91M | 2.9% |
| Accounts Receivable | $132.37M | -3.6% |
| Inventory | 96.5 | 10.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $312.89M | -11.4% |
| Short Term Debt | $47.77M | 14.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -0.02% | 5.1% |
| Return On Invested Capital | -6.68% | -1.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $25.26M | 67.4% |
| Operating Free Cash Flow | $25.94M | 71.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.25 | 4.61 | 4.07 | 2.96 | 38.45% |
| Price to Sales | 1.37 | 1.20 | 1.05 | 0.82 | 19.89% |
| Price to Tangible Book Value | -2.85 | -2.51 | -2.28 | -1.72 | 44.09% |
| Price to Free Cash Flow TTM | 27.26 | 18.77 | 24.91 | 13.61 | -73.17% |
| Enterprise Value to EBITDA | 54.09 | 42.05 | 57.40 | 27.12 | -33.94% |
| Free Cash Flow Yield | 3.7% | 5.3% | 4.0% | 7.3% | 272.68% |
| Return on Equity | -24.2% | -20.9% | -19.8% | -0.1% | -99.60% |
| Total Debt | $394.49M | $356.06M | $355.88M | $360.66M | -8.65% |
BVS earnings call for the period ending June 30, 2022.
BVS earnings call for the period ending March 31, 2022.
BVS earnings call for the period ending December 31, 2021.
BVS earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
